Top Abstract Purchase Related
Home
>
Node
>
Subnode

The evaluation of the efficacy of adjuvant laferon therapy in the combined treatment of patients with ovarian cancer based on the monitoring of the tumor marker Ca-125 in the blood serum

Zhyl'chuk, V.I.; Alistratov, O.V.; Vorontsova, A.L.

Likars'ka Sprava 2: 137-139

1998

ISSN/ISBN: 1019-5297
PMID: 9670686
Document Number: 494881
Relationship was established of blood level of CA-125 in patients with ovarian carcinoma (OC) to histologic form of tumour, with the highest CA-125 levels being recordable in patients with poorly differentiated OC, lower ones in those having serous form of OC, and the lowest in patients with mucinous form. Complex treatment schemes involving laferon make for striking and stable reduction of blood levels of CA-125 in patients presenting with serious and mucinous forms of OC and, strictly speaking, do not affect this same parameter in patients with poorly differentiated OC.

Document emailed within 1 workday
Secure & encrypted payments

Fioretti, P.; Gadducci, A.; Ferdeghini, M.; Bartolini, T.; Scatena, P.; Facchini, V.; Bianchi, R. 1986: Combined evaluation of some tumor associated antigens in the monitoring of integrated surgical and chemotherapeutic treatment of epithelial ovarian cancer European Journal of Gynaecological Oncology 7(3): 200-205
Zhyl'chuk, V.I. 1998: Increasing the efficacy of treating patients with extensive ovarian cancer by using laferon Likars'ka Sprava 3: 117-119
Sevelda, P.; Dittrich, C.; Salzer, H.; Pateisky, N.; Spona, J. 1986: Monitoring the cytotoxic potential of a sequential polychemotherapy (adriamycin/cisplatin-vincristine/cyclophosphamide-high dose methotrexate) in patients with advanced ovarian cancer with the tumor marker CA-125 Cancer Detection and Prevention 9(5-6): 521-528
Iwasaka, T.; Ohkuma, Y.; Yoshimura, T.; Sugimori, H. 1986: Clinical evaluation of specificity of serum CA125 as a tumor marker of ovarian carcinoma Nihon Sanka Fujinka Gakkai Zasshi 38(6): 917-923
Vinokurov, V.L.; Dudarev, A.L.; Jurkova, L.E.; Lapchenkov, V.I.; Barbanel, E.J. 1992: Tumor marker CA 125 in diagnosis, monitoring management and follow-up of patients with ovarian tumors European Journal of Gynaecological Oncology 13(2): 205-208
Schuurman, J.J.; Bong, S.B.; Einarsson, R. 1996: Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients Anticancer Research 16(4b): 2169-2172
Yonei, T.; Ohnoshi, T.; Hiraki, S.; Yamashita, H.; Ishii, J.; Egawa, T.; Kozuka, A.; Moritaka, T.; Uji, H.; Yoshida, M. 1988: Clinical evaluation of serum neuron-specific enolase as a tumor marker in lung cancer Nihon Kyobu Shikkan Gakkai Zasshi 26(2): 139-144
Tretiak, N.M.; Bondar, M.V.; Koval', A.I.; Slavchenko, I.I.; Mnyshenko, V.M.; Vakul'chuk, O.M.; Hordiienko, A.I. 1999: The use of Ukrainian laferon in the combined treatment of patients with chronic myeloid leukemia Likars'ka Sprava 5: 131-134
Suzuki, M.; Sekiguchi, I.; Tamada, T.; Sakurabayashi, I.; Kawai, T. 1985: Clinical evaluation of a cancer antigen CA125 associated with ovarian cancer. (III) Serum CA125 levels in patients with ovarian cancer and other gynecological tumors Rinsho Byori. Japanese Journal of Clinical Pathology 33(2): 173-177
Kobayashi, N.; Fujita, K.; Fujisawa, T.; Takahashi, H.; Yoneda, M.; Abe, Y.; Inamori, M.; Kirikoshi, H.; Kubota, K.; Saito, S.; Nakajima, A. 2008: Which is the best monitoring study (tumor marker, computed tomography or 18F-fluoro-2-deoxy-D-glucose positron emission tomography) to evaluate efficacy of chemotherapy on unresectable pancreatic cancer ? Gan to Kagaku Ryoho. Cancer and ChemoTherapy 35(1): 65-70
Sakurai, Y.; Kodaira, S.; Teramoto, T.; Sugano, K.; Abe, O.; Ohtake, H.; Iri, H. 1989: Clinical evaluation of serum level of NCC-ST-439 as a new tumor marker for colorectal diseases--fluctuation of serum NCC-ST-439 in patients with colorectal cancers before and after surgery Gan to Kagaku Ryoho. Cancer and ChemoTherapy 16(9): 3205-3212
Rose, D.P.; Davis, T.E. 1980: Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients Cancer Research 40(11): 4043-4047
Ubukata, H.; Katano, M.; Motohashi, G.; Kasuga, T.; Takemura, A.; Tabuchi, T.; Tabuchi, T. 2003: Evaluation of CA72-4 as a tumor marker in patients with gastric cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 30(11): 1821-1824
Markowska, J.; Lacki, J.K.; Jaroszewski, J.; Wiktorowicz, K. 1995: The usefulness of CD4/CD8 ratio evaluation in monitoring of ovarian cancer patients European Journal of Gynaecological Oncology 16(1): 54-58
Semiglazov, V.F.; Moiseenko, V.M.; Ivanova, O.A. 1986: Prospective randomized study of the efficacy of adjuvant hormone therapy in patients with breast cancer Voprosy Onkologii 32(8): 31-34
Bidziński, M.; Danska-Bidzińska, A.; Ziółkowska-Seta, I.; Derlatka, P.; Sobiczewski, P.; Raczyński, P. 2005: Analysis of the treatment of ovarian cancer patients with neo-adjuvant chemotherapy--preliminary results European Journal of Gynaecological Oncology 26(4): 423-426
Kopchak, V.M.; Todurov, I.M.; Stasenko, A.A.; Dronov, A.I.; Khomiak, I.V.; Serdiuk, V.P.; Gusev, A.V. 2002: The application of laferon in a combined therapy of purulent cholangitis Klinichna Khirurhiia 4: 27-29
Kimura, E.; Murae, M.; Koga, R.; Odawara, Y.; Nakabayashi, Y.; Yokoyama, K.; Nakata, H.; Totake, T.; Ochiai, K.; Yasuda, M. 1984: Clinical significance of new tumor marker CA 125 in gynecological cancer--particularly usefulness in diagnosis of ovarian cancer Nihon Sanka Fujinka Gakkai Zasshi 36(11): 2121-2128
Mastropaolo, W.; Fernandez, Z.; Miller, E.L. 1986: Pronounced increases in the concentration of an ovarian tumor marker, CA-125, in serum of a healthy subject during menstruation Clinical Chemistry 32(11): 2110-2111
Kudela, M.; Podivínský, R. 1979: Estimation of the uric acid concentration in the blood-serum during cytostatic therapy of ovarian cancer Ceskoslovenska Gynekologie 44(4): 282-284